GlassScriptPhysician profile
Steve I Wilkofsky
NPI 1396721254
$5,800.87
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $272 · 2021: $1,009 · 2022: $1,464 · 2023: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,711.32 | 2019-2023 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $622.28 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $488.99 | 2019-2023 | Gattex, Entyvio |
| Merck Sharp & Dohme LLC | $391.71 | 2019-2023 | Dificid |
| Micro-Tech Endoscopy USA, INC. | $348.06 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $272.16 | 2019-2023 | Ocaliva |
| Janssen Biotech, INC. | $265.78 | 2019-2023 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $238.12 | 2021-2023 | Zeposia |
| Pfizer INC. | $233.48 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $141.16 | 2019-2023 | Clenpiq |
| Nestle Healthcare Nutrition INC. | $117.79 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $100.87 | 2021-2023 | Linzess |
| Redhill Biopharma INC. | $97.98 | 2021-2022 | |
| Genzyme Corporation | $92.29 | 2022-2023 | |
| Ardelyx, INC. | $77.82 | 2022-2023 | Ibsrela |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $68.40 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $64.20 | 2022-2023 | Dupixent |
| Braintree Laboratories, INC. | $63.22 | 2021-2022 | |
| Evoke Pharma, INC. | $61.87 | 2020-2023 | Gimoti |
| Organon LLC | $59.83 | 2022-2023 | Hadlima, Renflexis |
| Qol Medical, LLC | $58.96 | 2019 | |
| Daiichi Sankyo INC. | $55.69 | 2019 | |
| Amgen INC. | $55.44 | 2020-2021 | |
| Alfasigma USA, INC. | $39.63 | 2020 | |
| Ucb, INC. | $19.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.43 | 2023 | |
| Endogastric Solutions, INC | $13.18 | 2019 | |
| Ethicon US, LLC | $12.58 | 2019 | |
| Allergan, INC. | $10.93 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Wilkofsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.